I 108th CONGRESS 2d Session H. R. 3858 IN THE HOUSE OF REPRESENTATIVES February 26, 2004 Mr. Nethercutt (for himself, Ms. DeGette, Mr. Bass, Mr. Schiff, Mr. Frost, Ms. Bordallo, Mr. Van Hollen, Mr. Kline, Mr. Green of Texas, Mr. Andrews, Mr. Wicker, Mr. Lantos, Mr. Becerra, Mr. Moore, Ms. DeLauro, Mr. McHugh, Mr. Weldon of Pennsylvania, and Mr. Fossella) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to increase the supply of pancreatic islet cells for research, and to provide for better coordination of Federal efforts and information on islet cell transplantation.

1.

Short title

This Act may be cited as the &short-title1;.

2.

Organ procurement organization certification

Section 371 of the Public Health Service Act (42 U.S.C. 273) is amended by adding at the end the following: (c)Pancreata procured by an organ procurement organization and used for islet cell transplantation or research shall be counted for purposes of certification or recertification under subsection (b)..

3.

Annual assessment on pancreatic islet cell transplantation

Section 429 of the Public Health Service Act (42 U.S.C. 285c–3) is amended by adding at the end the following: (d)In each annual report prepared by the Diabetes Mellitus Interagency Coordinating Committee pursuant to subsection (c), the Committee shall include an assessment of the Federal activities and programs related to pancreatic islet cell transplantation. Such assessment shall, at a minimum, address the following: (1)The adequacy of Federal funding for taking advantage of scientific opportunities relating to pancreatic islet cell transplantation. (2)Current policies and regulations affecting the supply of pancreata for islet cell transplantation. (3)The effect of xenotransplantation on advancing pancreatic islet cell transplantation. (4)The effect of United Network for Organ Sharing policies regarding pancreas retrieval and islet cell transplantation. (5)The existing mechanisms to collect and coordinate outcomes data from existing islet cell transplantation trials. (6)Implementation of multiagency clinical investigations of pancreatic islet cell transplantation. (7)Recommendations for such legislation and administrative actions as the Committee considers appropriate to increase the supply of pancreata available for islet cell transplantation..